Trial
NCT05205759
Non-inferiority Trial on Monoclonal Antibodies in COVID-19
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Collaborators
Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di Udine
Condition
COVID-19
Intervention
Bamlanivimab Etesevimab
Why stopped
Stop for futility after the onset of the omicron wave
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-26